GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Debt-to-Revenue

Coherus BioSciences (FRA:8C5) Debt-to-Revenue : 0.95 (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Coherus BioSciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1.5 Mil. Coherus BioSciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €241.7 Mil. Coherus BioSciences's annualized Revenue for the quarter that ended in Sep. 2024 was €255.1 Mil. Coherus BioSciences's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 0.95.


Coherus BioSciences Debt-to-Revenue Historical Data

The historical data trend for Coherus BioSciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Debt-to-Revenue Chart

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.88 1.28 2.28 1.87

Coherus BioSciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.61 1.31 1.56 1.04 0.95

Competitive Comparison of Coherus BioSciences's Debt-to-Revenue

For the Biotechnology subindustry, Coherus BioSciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Debt-to-Revenue falls into.



Coherus BioSciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Coherus BioSciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.967 + 438.965) / 235.893
=1.87

Coherus BioSciences's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.468 + 241.69) / 255.068
=0.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Coherus BioSciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Coherus BioSciences Headlines

No Headlines